Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
Article
New appointments at City of Hope, UA, and Fox Chase
The University of Arizona (UA) Cancer Center has a new interim director, two hematologists have earned new positions at City of Hope, and an...
Article
Endoscopic treatment effective in T1b esophageal cancer
A systematic review suggests endoscopic treatment is appropriate for T1b esophageal cancers with a low risk of metastasis.
Video
SC daratumumab deemed feasible for every multiple myeloma patient
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
News
CNS-directed therapy appears more effective for synDLBCL
Two-year survival rates were superior among patients who received CNS-intensive therapy.
Article
Hemostasis researcher passes away at age 72
Dr. George J. Broze, who is known for his research on hemostasis and the relationship between coagulation and inflammation, died following a heart...
News
‘Robust antitumor immune responses’ observed in pediatric ALL
Tumor-associated CD8+ T cells responded to 86% of neoantigens tested and recognized 68% of neoepitopes tested in samples from pediatric ALL...
News
BET inhibitors may target oncogene in ABC-like DLBCL
Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.
News
‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCL
CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.
Article
Stand Up To Cancer adds research muscle
Dr. John D. Carpten and Dr. Roderic I. Pettigrew have joined the Stand Up To Cancer scientific advisory committee. And Fox Chase Cancer Center in...
News
R2 appears active in high-risk FL and MZL
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
News
Triplet offers longest PFS yet seen in relapsed/refractory myeloma
CHICAGO – Patients who received isatuximab plus pomalidomide and dexamethasone had a median progression-free survival of 11.53 months.
News
Four-drug combo bests triplet in newly diagnosed myeloma
CHICAGO – Results with daratumumab plus bortezomib, thalidomide, and dexamethasone are the “best ever reported in the setting of stem cell...
News
Adding ipilimumab to nivolumab provides no benefit in SCC trial
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...
News
Pregnancy deemed safe in BRCA-mutated breast cancer survivors
Pregnancy did not affect disease-free or overall survival, and complications were similar to the general population.
News
Inhibitor produces high response rate in relapsed/refractory FL
CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of...